Analysis of scant cancer cells in fine needle aspirates

细针抽吸物中少量癌细胞的分析

基本信息

项目摘要

 DESCRIPTION (provided by applicant): Comprehensive analysis of key cancer proteins and pathway markers in clinical samples remains challenging yet is critical in assessing efficacy of molecularly targeted drugs in clinical trial and in understanding complex tumor biology. Currently, the number of markers being studies is often limited (<10) and requires time- consuming analyses of tissue sections harvested by large core biopsies which carry a not insignificant morbidity. We developed a technology that allows simultaneous analysis of hundreds of proteins in cancer cells harvested from fine needle aspirates (FNA). The method capitalizes on DNA-barcoded antibody sensing where barcodes are photo-cleaved and digitally detected without any amplification steps. In a recent proof-of- concept study (Sci Transl Med 2014;6: 219ra9) this method showed high reproducibility, achieved single cell sensitivity and was able to identify pathway responses to molecularly targeted drugs, even in single cells. Compared to existing technology (immunohistochemistry, cytometry and mass spectrometry) it: i) allows hundreds of markers to be detected simultaneously, ii) works well in single cells or small numbers of cells, iii) does not destroy valuable samples, iv) is fast and inexpensive and v) can be combined with mRNA and DNA analytical techniques. The goal of this R33 application is to further the technology by integrating it with i) on-chip microfluidics for cancer cell enrichmen and single/bulk cell harvesting and ii) combined protein, mRNA and DNA analysis. We will then expand and rigorously test this next generation device for point-of-care analyses of single cells in two clinical studies to broadly demonstrate its broad cancer utility: i) in a clinical diagnosti study to compare cancer cell protein profiles in breast cancer patients and ii) in a drug trial of PI3K inhibition to determine treatment response/failure over time. The proposed integrated profiling method has the potential to transform cancer research and clinical practice. It will allo inexpensive, more extensive and robust profiling of cellular markers in scant and valuable materials from clinical trials.
 描述(由申请人提供):临床样本中关键癌症蛋白和途径标志物的综合分析仍然具有挑战性,但对于评估临床试验中分子靶向药物的疗效和理解复杂的肿瘤生物学至关重要。目前,正在研究的标记物的数量通常是有限的(<10),并且需要对通过大的核心活检收获的组织切片进行耗时的分析,所述组织切片具有不小的发病率。我们开发了一种技术,可以同时分析从细针抽吸物(FNA)中收获的癌细胞中的数百种蛋白质。该方法利用DNA条形码化抗体感测,其中条形码被光切割并在没有任何扩增步骤的情况下进行数字检测。在最近的概念验证研究(Sci Transl Med 2014; 6:219ra9)中,该方法显示出高再现性,实现了单细胞灵敏度,并且能够鉴定对分子靶向药物的途径响应,即使在单细胞中。与现有技术(免疫组织化学、细胞计量术和质谱法)相比,它:i)允许同时检测数百种标志物,ii)在单个细胞或少量细胞中工作良好,iii)不破坏有价值的样品,iv)快速且便宜,以及v)可以与mRNA和DNA分析技术组合。该R33应用的目标是通过将其与i)用于癌细胞富集和单个/大量细胞收获的芯片上微流体和ii)组合的蛋白质、mRNA和DNA分析相集成来进一步发展该技术。然后,我们将在两项临床研究中扩展并严格测试这种下一代设备,用于单细胞的即时分析,以广泛证明其广泛的癌症效用:i)在临床诊断研究中比较乳腺癌患者的癌细胞蛋白质谱,ii)在PI3K抑制的药物试验中确定随时间的治疗反应/失败。提出的综合分析方法有可能改变癌症研究和临床实践。它将允许廉价,更广泛和强大的分析细胞标记物的稀缺和有价值的材料从临床试验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RALPH WEISSLEDER, MD, PHD其他文献

RALPH WEISSLEDER, MD, PHD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RALPH WEISSLEDER, MD, PHD', 18)}}的其他基金

Bioorthogonal probe development for highly parallel in vivo imaging
用于高度并行体内成像的生物正交探针开发
  • 批准号:
    10596786
  • 财政年份:
    2023
  • 资助金额:
    $ 43.33万
  • 项目类别:
Temporal analysis of the GBM tumor microenvironment during myeloid cell activating therapy
骨髓细胞激活治疗期间 GBM 肿瘤微环境的时间分析
  • 批准号:
    10704328
  • 财政年份:
    2023
  • 资助金额:
    $ 43.33万
  • 项目类别:
Ultrasenstive vesicle analysis in precancerous pancreatic neoplasm (IPMN)
癌前胰腺肿瘤 (IPMN) 的超灵敏囊泡分析
  • 批准号:
    10615899
  • 财政年份:
    2020
  • 资助金额:
    $ 43.33万
  • 项目类别:
Ultrasenstive vesicle analysis in precancerous pancreatic neoplasm (IPMN)
癌前胰腺肿瘤 (IPMN) 的超灵敏囊泡分析
  • 批准号:
    10403494
  • 财政年份:
    2020
  • 资助金额:
    $ 43.33万
  • 项目类别:
Single Circulating Vesicle Analysis for Early Cancer Detection
用于早期癌症检测的单循环囊泡分析
  • 批准号:
    9913496
  • 财政年份:
    2019
  • 资助金额:
    $ 43.33万
  • 项目类别:
Imaging of nanotherapeutic drug action
纳米治疗药物作用的成像
  • 批准号:
    9261150
  • 财政年份:
    2017
  • 资助金额:
    $ 43.33万
  • 项目类别:
Multiplexed analysis of exosomes in cancer nano therapy
癌症纳米疗法中外泌体的多重分析
  • 批准号:
    9078198
  • 财政年份:
    2016
  • 资助金额:
    $ 43.33万
  • 项目类别:
Multiplexed analysis of exosomes in cancer nano therapy
癌症纳米疗法中外泌体的多重分析
  • 批准号:
    9487955
  • 财政年份:
    2016
  • 资助金额:
    $ 43.33万
  • 项目类别:
Analysis of scant cancer cells in fine needle aspirates
细针抽吸物中少量癌细胞的分析
  • 批准号:
    9324962
  • 财政年份:
    2016
  • 资助金额:
    $ 43.33万
  • 项目类别:
Single Cell Imaging of the Heart
心脏的单细胞成像
  • 批准号:
    9265709
  • 财政年份:
    2014
  • 资助金额:
    $ 43.33万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 43.33万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.33万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 43.33万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.33万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 43.33万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 43.33万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.33万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 43.33万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 43.33万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 43.33万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了